XIAP and ovarian carcinoma: Moreover, even though McManus et al. (38) demonstrated that XIAP knockdown sensitized breast cancer cells to taxanes, but not to CPT, recent data by Zhang et al. (62) highlighted that XIAP high-expressing ovarian cancer patients were less likely to respond to CPT treatment and showed that XIAP knockdown in ovarian cancer cell lines slowed their proliferation kinetics, on one hand, and sensitized them to this drug in vitro, on the other.